-DOCSTART- -X- O
Macrophage-mediated -X- _ B-Intervention
programmed -X- _ I-Intervention
cell -X- _ I-Intervention
removal -X- _ I-Intervention
( -X- _ I-Intervention
PrCR -X- _ I-Intervention
) -X- _ I-Intervention
is -X- _ O
a -X- _ O
process -X- _ O
essential -X- _ O
for -X- _ O
the -X- _ O
clearance -X- _ O
of -X- _ O
unwanted -X- _ O
( -X- _ O
damaged -X- _ O
, -X- _ O
dysfunctional -X- _ O
, -X- _ O
aged -X- _ O
, -X- _ O
or -X- _ O
harmful -X- _ O
) -X- _ O
cells. -X- _ O
The -X- _ O
detection -X- _ O
and -X- _ O
recognition -X- _ O
of -X- _ O
appropriate -X- _ O
target -X- _ O
cells -X- _ O
by -X- _ O
macrophages -X- _ O
is -X- _ O
a -X- _ O
critical -X- _ O
step -X- _ O
for -X- _ O
successful -X- _ O
PrCR -X- _ B-Patient
, -X- _ O
but -X- _ O
its -X- _ O
molecular -X- _ O
mechanisms -X- _ O
have -X- _ O
not -X- _ O
been -X- _ O
delineated. -X- _ O
Here -X- _ O
using -X- _ O
the -X- _ O
models -X- _ O
of -X- _ O
tissue -X- _ B-Patient
turnover -X- _ I-Patient
, -X- _ O
cancer -X- _ B-Patient
immunosurveillance -X- _ I-Patient
, -X- _ O
and -X- _ O
hematopoietic -X- _ B-Patient
stem -X- _ I-Patient
cells -X- _ I-Patient
, -X- _ O
we -X- _ O
show -X- _ O
that -X- _ O
unwanted -X- _ O
cells -X- _ O
such -X- _ O
as -X- _ O
aging -X- _ O
neutrophils -X- _ O
and -X- _ O
living -X- _ O
cancer -X- _ O
cells -X- _ O
are -X- _ O
susceptible -X- _ O
to -X- _ O
“labeling” -X- _ B-Intervention
by -X- _ I-Intervention
secreted -X- _ I-Intervention
calreticulin -X- _ I-Intervention
( -X- _ I-Intervention
CRT -X- _ I-Intervention
) -X- _ I-Intervention
from -X- _ I-Intervention
macrophages -X- _ I-Intervention
, -X- _ O
enabling -X- _ O
their -X- _ O
clearance -X- _ O
through -X- _ O
PrCR. -X- _ B-Patient
Importantly -X- _ O
, -X- _ O
we -X- _ O
identified -X- _ B-Outcome
asialoglycans -X- _ I-Outcome
on -X- _ I-Outcome
the -X- _ I-Outcome
target -X- _ I-Outcome
cells -X- _ I-Outcome
to -X- _ I-Outcome
which -X- _ I-Outcome
CRT -X- _ I-Outcome
binds -X- _ I-Outcome
to -X- _ I-Outcome
regulate -X- _ I-Outcome
PrCR -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
availability -X- _ I-Outcome
of -X- _ I-Outcome
such -X- _ I-Outcome
CRT-binding -X- _ I-Outcome
sites -X- _ I-Outcome
on -X- _ I-Outcome
cancer -X- _ I-Outcome
cells -X- _ I-Outcome
correlated -X- _ I-Outcome
with -X- _ I-Outcome
the -X- _ I-Outcome
prognosis -X- _ I-Outcome
of -X- _ I-Outcome
patients -X- _ I-Outcome
in -X- _ I-Outcome
various -X- _ I-Outcome
malignancies. -X- _ I-Outcome
Our -X- _ O
study -X- _ O
reveals -X- _ O
a -X- _ O
general -X- _ O
mechanism -X- _ O
of -X- _ O
target -X- _ O
cell -X- _ O
recognition -X- _ O
by -X- _ O
macrophages -X- _ O
, -X- _ O
which -X- _ O
is -X- _ O
the -X- _ O
key -X- _ O
for -X- _ O
the -X- _ O
removal -X- _ O
of -X- _ O
unwanted -X- _ O
cells -X- _ O
by -X- _ O
PrCR -X- _ B-Patient
in -X- _ O
physiological -X- _ O
and -X- _ O
pathophysiological -X- _ O
processes -X- _ O
. -X- _ O

